Cargando…

Hepatic profile analyses of tipranavir in Phase II and III clinical trials

BACKGROUND: The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials (TPV/r-ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mikl, Jaromir, Sulkowski, Mark S, Benhamou, Yves, Dieterich, Douglas, Pol, Stanislas, Rockstroh, Jürgen, Robinson, Patrick A, Ranga, Mithun, Stern, Jerry O
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803791/ https://www.ncbi.nlm.nih.gov/pubmed/20003457 http://dx.doi.org/10.1186/1471-2334-9-203

Ejemplares similares

Review of tipranavir in the treatment of drug-resistant HIV
por: Streeck, Hendrik, et al.
Publicado: (2007)

Tipranavir in the Protease Inhibitors Arena
por: Vergani, Barbara, et al.
Publicado: (2012)

Role of tipranavir in treatment of patients with multidrug-resistant HIV
por: Courter, Joshua D, et al.
Publicado: (2010)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
por: Stefanik, Michal, et al.
Publicado: (2020)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
por: Elgadi, Mabrouk M., et al.
Publicado: (2012)

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure
por: Hsieh, Szu-Min, et al.
Publicado: (2009)

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands
por: Hubben, Gijs AA, et al.
Publicado: (2007)

Chemoinformatic Design and Profiling of Derivatives of Dasabuvir, Efavirenz, and Tipranavir as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase and Methyltransferase
por: Ezeh, Madeleine I., et al.
Publicado: (2022)

Therapeutic issues in HIV/HCV-coinfected patients
por: Sulkowski, M S, et al.
Publicado: (2007)

What happens after hepatitis C eradication?
por: Pol, Stanislas
Publicado: (2012)

Late presentation of chronic viral hepatitis for medical care: a consensus definition
por: Mauss, Stefan, et al.
Publicado: (2017)

Validation of the shortened Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS)
por: Mattera, Maria, et al.
Publicado: (2018)

The treatment of chronic hepatitis C virus infection in HIV co-infection
por: Vogel, Martin, et al.
Publicado: (2009)

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
por: Rockstroh, Jürgen K, et al.
Publicado: (2013)

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
por: Indu, Purushothaman, et al.
Publicado: (2020)

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
por: Berhan, Asres, et al.
Publicado: (2013)

Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the Caregiver Impact Questionnaire
por: Harrington, Magdalena, et al.
Publicado: (2019)

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
por: Cooper, David A., et al.
Publicado: (2016)

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
por: Casado, JL, et al.
Publicado: (2010)

HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?
por: Rockstroh, Jürgen Kurt, et al.
Publicado: (2019)

Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe
por: Lazarus, Jeffrey V, et al.
Publicado: (2016)

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant
por: Ratziu, Vlad, et al.
Publicado: (2006)

Distinct CD4(+)CD8(+) Double-Positive T Cells in the Blood and Liver of Patients during Chronic Hepatitis B and C
por: Nascimbeni, Michelina, et al.
Publicado: (2011)

Analysis of Daily Sleep Diary Measures From Multilayer Extended-Release Methylphenidate (PRC-063) Studies in Children and Adults With ADHD
por: Cataldo, Marc, et al.
Publicado: (2022)

Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort
por: Chan, Austin, et al.
Publicado: (2019)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol, Stanislas, et al.
Publicado: (2016)

Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype
por: Abdoul, Hendy, et al.
Publicado: (2008)

The path to hepatitis C elimination: who are we leaving behind and why?
por: Rockstroh, Jurgen K., et al.
Publicado: (2023)

Higgs analyses at LHC - III
por: Jakobs, Karl
Publicado: (2013)

Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection
por: Rivière, Yves, et al.
Publicado: (2012)

Mild and Efficient Heterogeneous Hydrogenation of Nitroarenes Facilitated by a Pyrolytically Activated Dinuclear Ni(II)-Ce(III) Diimine Complex
por: Michalke, Jessica, et al.
Publicado: (2022)

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
por: Leroy, Vincent, et al.
Publicado: (2016)

Managing antiretrovirals in co-infected patients in 2012
por: Rockstroh, Jürgen
Publicado: (2012)

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective
por: Peters, Lars, et al.
Publicado: (2014)

MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
por: Martel-Laferrière, Valérie, et al.
Publicado: (2014)

Changes to the Natural Killer Cell Repertoire after Therapeutic Hepatitis B DNA Vaccination
por: Scott-Algara, Daniel, et al.
Publicado: (2010)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection
por: Sarrazin, Christoph, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sa4cdvuunupv7g12cj2qfb4ell